Victoza · Saxenda · daily GLP-1 agonist
Liraglutide
Label FDA-approved
What it is
Liraglutide is a daily GLP-1 receptor agonist. Saxenda and Victoza are approved products with different labeled ceilings. Research-chemical material is not those pens.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- Daily GLP-1 shot (Victoza / Saxenda). Older sibling of weekly semaglutide.
- Same family benefits: appetite down, glucose handling up, weight change on the approved labels.
- Daily injection is the inconvenience vs newer weeklies.
- Label product ≠ research syringe.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
GLP-1 receptor activation: glucose-dependent insulin, delayed gastric emptying, central appetite effects. Daily dosing tracks the shorter half-life versus semaglutide.
Possible side effects / caveats
GI titration effects, gallbladder disease, pancreatitis warning language, rodent thyroid C-cell boxed warning, hypoglycemia with insulin or sulfonylureas.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Label (Saxenda) | 0.6 → 3.0 mg | Daily; increase by 0.6 mg weekly as tolerated | Weight-management ceiling on the insert |
| Label (Victoza) | 0.6 → 1.2–1.8 mg | Daily | Diabetes titration |